Liquidia Corp

NASDAQ:LQDAUnited States

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

Contact Information

Headquarters

419 Davis Drive, Suite 100MORRISVILLE, NC, United States 27560

Phone

919-328-4400

Fax

919-328-4402

Executives

Independent Chairman of the board

Stephen Bloch

Chief Executive Officer, Director

Roger Jeffs

Chief Financial Officer, Chief Operating Officer

Michael Kaseta

General Counsel, Secretary

Russell Schundler

Chief Commercial Officer

Scott Moomaw